Expert Opinion on Drug Safety

Drugs in the elderly - more good than harm?
pp. 229-231(3)
Author: Beard, Keith

Eliminating error-prone notations in medical communications
pp. 233-234(2)
Author: von Eschenbach, Andrew C

Deferasirox: uncertain future following renal failure fatalities, agranulocytosis and other toxicities
pp. 235-239(5)
Author: Kontoghiorghes, George J

The safety of levetiracetam
pp. 241-250(10)
Authors: Sirsi, Deepa; Safdieh, Joseph E

The adverse effects of antiepileptic drugs in children
pp. 251-265(15)
Authors: Kothare, Sanjeev V; Kaleyias, Joseph

Adverse effects of antiepileptic drugs on bone mineral density in children
pp. 267-278(12)
Authors: Gissel, Tina; Poulsen, Carsten Søndergaard; Vestergaard, Peter

The safety and efficacy of IFN-β products for the treatment of multiple sclerosis
pp. 279-288(10)
Authors: Kremenchutzky, Marcelo; Morrow, Sarah; Rush, Carolina

Methadone-associated long QT syndrome: improving pharmacotherapy for dependence on illegal opioids and lessons learned for pharmacology
pp. 289-303(15)
Authors: Ehret, Georg B; Desmeules, Jules A; Broers, Barbara

The safety of zoledronic acid
pp. 305-313(9)
Author: Lipton, Allan

Managing cardiotoxicity in anthracycline-treated breast cancers
pp. 315-321(7)
Authors: Ng, Raymond; Green, Michael D

Non-chemotherapy drug-induced agranulocytosis
pp. 323-335(13)
Author: Garbe, Edeltraut